[go: up one dir, main page]

NO20032233L - Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer - Google Patents

Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer

Info

Publication number
NO20032233L
NO20032233L NO20032233A NO20032233A NO20032233L NO 20032233 L NO20032233 L NO 20032233L NO 20032233 A NO20032233 A NO 20032233A NO 20032233 A NO20032233 A NO 20032233A NO 20032233 L NO20032233 L NO 20032233L
Authority
NO
Norway
Prior art keywords
renin inhibitor
cardiovascular diseases
synergistic compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20032233A
Other languages
English (en)
Other versions
NO20032233D0 (no
NO334002B1 (no
Inventor
William Hewitt
Daniel Lucius Vasella
Randy Lee Webb
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032233(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of NO20032233D0 publication Critical patent/NO20032233D0/no
Publication of NO20032233L publication Critical patent/NO20032233L/no
Publication of NO334002B1 publication Critical patent/NO334002B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
NO20032233A 2000-11-17 2003-05-16 Farmasøytisk sammensetning som omfatter renininhibitoren aliskiren, og minst ett ytterligere terapeutisk middel, anvendelse derav, samt kitt NO334002B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
PCT/EP2001/013241 WO2002040007A1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Publications (3)

Publication Number Publication Date
NO20032233D0 NO20032233D0 (no) 2003-05-16
NO20032233L true NO20032233L (no) 2003-05-16
NO334002B1 NO334002B1 (no) 2013-11-11

Family

ID=9903412

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20032233A NO334002B1 (no) 2000-11-17 2003-05-16 Farmasøytisk sammensetning som omfatter renininhibitoren aliskiren, og minst ett ytterligere terapeutisk middel, anvendelse derav, samt kitt
NO2013019C NO2013019I1 (no) 2000-11-17 2013-12-17 Kombinasjon omfattende aliskiren, som den frie basen eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2013019C NO2013019I1 (no) 2000-11-17 2013-12-17 Kombinasjon omfattende aliskiren, som den frie basen eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.

Country Status (31)

Country Link
US (4) US8168616B1 (no)
EP (7) EP1930000A1 (no)
JP (6) JP2004513920A (no)
KR (6) KR20080096715A (no)
CN (4) CN100404024C (no)
AT (2) ATE397445T1 (no)
AU (2) AU2002223680B2 (no)
BR (1) BR0115411A (no)
CA (2) CA2763223A1 (no)
CY (5) CY1105603T1 (no)
CZ (2) CZ305341B6 (no)
DE (3) DE122009000021I1 (no)
DK (3) DK1602370T3 (no)
EC (1) ECSP034603A (no)
ES (4) ES2429292T3 (no)
GB (1) GB0028151D0 (no)
HU (2) HUP0301841A3 (no)
IL (3) IL155707A (no)
LU (2) LU91563I2 (no)
MX (1) MXPA03004358A (no)
NL (2) NL300385I1 (no)
NO (2) NO334002B1 (no)
NZ (6) NZ568764A (no)
PL (3) PL400915A1 (no)
PT (3) PT1602370E (no)
RU (2) RU2310443C2 (no)
SG (1) SG135969A1 (no)
SI (3) SI1915993T1 (no)
SK (1) SK287881B6 (no)
WO (1) WO2002040007A1 (no)
ZA (1) ZA200303497B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
AU2003255527A1 (en) * 2002-06-28 2004-01-19 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
CN1882528A (zh) 2003-11-26 2006-12-20 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
WO2005070871A2 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their activity as renin inhibitors
US7767690B2 (en) 2004-01-23 2010-08-03 Novartis Ag Amino alcohol derivatives and their use as renin inhibitor
US7718675B2 (en) * 2004-01-23 2010-05-18 Speedel Experimenta Ag Diamino alcohols and their use as renin inhibitor
NZ586285A (en) * 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
CA2560195A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
CN101102755B (zh) * 2004-10-08 2013-01-02 诺瓦提斯公司 肾素抑制剂在制备预防或治疗舒张功能障碍或舒张性心力衰竭的药物中的用途
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
MX2007013471A (es) * 2005-04-27 2008-01-22 Novartis Ag Metodos de tratamiento de aterosclerosis.
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
DK1797885T3 (da) * 2005-09-28 2008-07-14 Teva Pharma Stabil kombination af amlodipinbesylat og benazeprilhydrochlorid
RU2008122712A (ru) * 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2008136317A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Способы и композиции для лечения диагностикой сердечной недостаточности
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
JP2010513300A (ja) * 2006-12-15 2010-04-30 ノバルティス アーゲー 肥満患者における高血圧の予防および処置のためのレニン阻害剤
EP2120899A1 (en) * 2007-02-14 2009-11-25 Gilead Colorado, Inc. Antihypertensive drug combination
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
US20110111021A1 (en) 2008-02-22 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical preparation
US20110111022A1 (en) 2008-04-10 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical formulation
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
AR075880A1 (es) 2009-03-20 2011-05-04 Novartis Ag Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo.
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
WO2012152718A1 (en) 2011-05-06 2012-11-15 Farmicom Pharmaceutical Company D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
SG11201407200TA (en) * 2012-05-18 2014-12-30 Luoda Pharma Pty Ltd Liquid formulation
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
BR112017001758A2 (pt) 2014-07-30 2017-11-21 Merck Patent Gmbh álcoois polivinílicos diretamente compressíveis
CA3040803A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
ES2142789T3 (es) 1989-06-14 2000-05-01 Smithkline Beecham Corp Acidos imidazolil-alquenoicos.
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
RU2147875C1 (ru) * 1990-05-11 2000-04-27 Пфайзер Инк. Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
WO1992003429A1 (en) * 1990-08-15 1992-03-05 Abbott Laboratories Renin inhibitors
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
DE69131021T2 (de) 1990-12-14 1999-08-12 Smithkline Beecham Corp., Philadelphia, Pa. 19101 Angiotensin-ii-rezeptor blockierende zusammensetzungen
AU1256692A (en) 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (no) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
NZ266314A (en) 1993-04-27 1998-10-28 Smithkline Beecham Corp Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
EP0634175B1 (de) * 1993-07-15 2001-01-10 F. Hoffmann-La Roche Ag Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
DK0714897T3 (da) 1993-08-18 2001-03-19 Banyu Pharma Co Ltd Ring-kondenseret heteroaromatisk cyclopentenderivat med endothelinantagonist-aktivitet
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
DE69527072T2 (de) 1994-08-19 2003-02-13 Abbott Laboratories, Abbott Park Endothelin antagoniste
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (no) 1994-12-20 1997-08-21 Hoffmann La Roche
PL184060B1 (pl) 1995-01-27 2002-08-30 Rhone Poulenc Rorer Ltd Podstawione związki fenylowe do zastosowania jako środki antagonistyczne endoteliny
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
ATE201202T1 (de) 1995-12-20 2001-06-15 Yamanouchi Pharma Co Ltd Arylethensulfonamid-derivate und diese enthaltende medikamente
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
CA2249330C (en) 1996-04-04 2005-08-09 Banyu Pharmaceutical Co., Ltd. Method of treating heart failure with endothelin antagonists
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6517871B1 (en) 1998-07-20 2003-02-11 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
JP2003511347A (ja) * 1999-03-19 2003-03-25 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御
CA2390561A1 (en) 1999-11-09 2001-05-17 Pharmacia Corporation Use of an aldosterone antagonist for treating restenosis
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
ATE397147T1 (de) 2002-12-31 2008-06-15 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
PT1341533E (pt) 2006-06-30
KR20110063596A (ko) 2011-06-10
HU230882B1 (hu) 2018-11-29
US20120016035A1 (en) 2012-01-19
IL155707A0 (en) 2003-11-23
ZA200303497B (en) 2004-04-28
SI1341533T1 (sl) 2006-08-31
PL227576B1 (pl) 2017-12-29
CN101091703A (zh) 2007-12-26
JP2009235107A (ja) 2009-10-15
RU2346703C2 (ru) 2009-02-20
JP2004513920A (ja) 2004-05-13
EP2305233A1 (en) 2011-04-06
JP6373931B2 (ja) 2018-08-15
NO20032233D0 (no) 2003-05-16
LU92315I2 (fr) 2014-01-27
HUP0301841A3 (en) 2010-07-28
HK1115544A1 (en) 2008-12-05
EP1915993A1 (en) 2008-04-30
HU1400409D0 (hu) 2003-09-29
RU2310443C2 (ru) 2007-11-20
ATE317692T1 (de) 2006-03-15
EP1602370B1 (en) 2008-06-04
CA2428647A1 (en) 2002-05-23
NO2013019I2 (no) 2013-12-17
CY1105603T1 (el) 2010-07-28
NZ568764A (en) 2009-11-27
PL400915A1 (pl) 2012-12-17
KR20100114904A (ko) 2010-10-26
ES2256335T3 (es) 2006-07-16
IL217847A0 (en) 2012-03-29
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
SK287881B6 (sk) 2012-02-03
HK1059212A1 (en) 2004-06-25
DE60134349D1 (de) 2008-07-17
IL212075A (en) 2013-08-29
IL212075A0 (en) 2011-06-30
EP2305231A1 (en) 2011-04-06
ECSP034603A (es) 2003-06-25
CY1108305T1 (el) 2012-01-25
BR0115411A (pt) 2004-08-17
MXPA03004358A (es) 2003-08-19
CZ305341B6 (cs) 2015-08-05
CN101264072A (zh) 2008-09-17
CN100404024C (zh) 2008-07-23
EP2305232B1 (en) 2019-07-17
SI1602370T1 (sl) 2008-10-31
ES2734523T3 (es) 2019-12-10
PL400914A1 (pl) 2012-12-17
CZ299749B6 (cs) 2008-11-12
AU2368002A (en) 2002-05-27
EP1341533B1 (en) 2006-02-15
US20120010295A1 (en) 2012-01-12
IL155707A (en) 2012-02-29
LU91563I2 (fr) 2009-07-06
CA2763223A1 (en) 2002-05-23
HUP0301841A2 (hu) 2003-09-29
KR101008752B1 (ko) 2011-01-14
KR20080097488A (ko) 2008-11-05
PT1602370E (pt) 2008-09-10
US8168616B1 (en) 2012-05-01
EP1602370A2 (en) 2005-12-07
CN1474690A (zh) 2004-02-11
EP1341533A1 (en) 2003-09-10
JP6603757B2 (ja) 2019-11-06
HK1089356A1 (en) 2006-12-01
JP2013213061A (ja) 2013-10-17
EP2305232A1 (en) 2011-04-06
SI1915993T1 (sl) 2013-10-30
ES2308347T3 (es) 2008-12-01
NL301005I2 (nl) 2019-10-29
CY1114829T1 (el) 2015-11-04
SG135969A1 (en) 2007-10-29
JP2017019876A (ja) 2017-01-26
JP2018131465A (ja) 2018-08-23
EP1602370A3 (en) 2005-12-14
US8618174B2 (en) 2013-12-31
DE60117295D1 (de) 2006-04-20
DE122009000021I1 (de) 2009-08-06
NL300385I1 (nl) 2009-07-01
PL361404A1 (en) 2004-10-04
DK1341533T3 (da) 2006-05-08
EP1915993B1 (en) 2013-07-10
JP6577994B2 (ja) 2019-09-18
US20120004312A1 (en) 2012-01-05
WO2002040007A1 (en) 2002-05-23
DK1915993T3 (da) 2013-10-14
NO334002B1 (no) 2013-11-11
NO2013019I1 (no) 2014-06-02
KR101258365B1 (ko) 2013-04-30
DE60117295T2 (de) 2006-08-17
NZ550897A (en) 2008-03-28
DK1602370T3 (da) 2008-09-22
NZ550898A (en) 2008-07-31
ES2429292T3 (es) 2013-11-14
NZ537691A (en) 2007-01-26
AU2002223680B2 (en) 2005-04-07
CY2009005I1 (el) 2012-01-25
CY2013045I1 (el) 2015-11-04
NZ525795A (en) 2005-03-24
NL301005I1 (no) 2019-09-10
SK5842003A3 (en) 2003-11-04
KR20080011355A (ko) 2008-02-01
ATE397445T1 (de) 2008-06-15
CN101264073A (zh) 2008-09-17
KR20080096715A (ko) 2008-10-31
KR20030051753A (ko) 2003-06-25
CY2009005I2 (el) 2012-01-25
GB0028151D0 (en) 2001-01-03
US9023893B2 (en) 2015-05-05
RU2006132668A (ru) 2008-03-20
JP2018030894A (ja) 2018-03-01
JP6089278B2 (ja) 2017-03-08
US9023894B2 (en) 2015-05-05
EP1930000A1 (en) 2008-06-11
CY2013045I2 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
AU3664401A (en) Platelet adp receptor inhibitors
EP1734041A3 (en) Platelet ADP receptor inhibitors
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
EP1619180A4 (en) CASR ANTAGONIST
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
RU2000128859A (ru) Способ защиты печени от ксенобиотиков в эксперименте

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS PHARMA AG, CH

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: RASILEZ HCT; REG. NO/DATE: EU/1/08/491/001-080 20090219

Spc suppl protection certif: 2013019

Filing date: 20131217

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: RASILEZ HCT; REG. NO/DATE: EU/1/08/491/001-080 20090219

Spc suppl protection certif: 2013019

Filing date: 20131217

Extension date: 20231028

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NODEN PHARMACEUTICALS DAC, IE

MM1K Lapsed by not paying the annual fees